Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
A PATH TO A CURE
Leaders of Acute Myeloid Leukemia Research
Jasmine Nguyen
Izabel Torres
Ulysses Andrade
All Children and Adults Affected with Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia is a very aggressive and progressive form of leukemia diagnosed in adults and young children.
1.
: Increase survival rates within patients who are diagnosed with AML
2.
Lower diagnosis numbers in patients with a form of leukemia
3.
Increase survival rate from treatment for AML
-patients will have specific enzymes, proteins and molecules that assist tumor tissue in its production.
By receiving the proper funding, research on improving targeted therapy could surpass chemotherapy and radiation therapy. The more research found on targeted therapy:
Solution
Problem:
Projected Result
Goal is to be able to utilize the research gained from targeted therapy to apply it as an acceptable form of treatment for patients with AML
If government funding can aid in the creation of educational clinics and promising clinical trials, then children and adults would become more aware of the warning signs and treatment through clinical trials, specifically through “Targeted Therapy”.
Acute Myeloid Leukemia is a rare form of cancer of the blood in which there are too many immature white blood cells being produced from the bone marrow.
1. Before the initial project takes off, the first priority of the clinical trial will be to find the appropriate pool of subjects.
2. The criteria will be
1. Hematologist-oncologist will be responsible for finding patients who are suitable for this research
2. A consensual NDA form, that will prevent any research from leaving the facility and in case of a lawsuit that a subject may bring up in the future
3. These preparations are meant to take no longer than 2 months.
1. The first three months of trial will be used to find the appropriate dosage per subject.
-General Physicians and Dieticians
2. Once the proper dosages are implemented, the patients are to receive targeted therapy daily.
-Hematologist-Oncologist
3. As the clinical trial continues, the medication and treatment will be further more developed where it will be less rigorous and invasive
-The bi-weekly reports that were taken within the span of the trial will show that the excess of immature white blood cells have lowered significantly--
Stage 1
-finding 20 patients
-NDA Forms
Stage 2
-educational consultation
-blood withdraws
-pretreatment
Stage 3
-The next three months of trial will be used to find the appropriate dosage per subject.
Time